CASE REPORT article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1569124
Immune Checkpoint Inhibitor Therapy for Advanced HPV-Related Penile Squamous Cell Carcinoma: A Rare Case Report
Provisionally accepted
- 1Department of General Surgery, Beijing Yanqing Hospital of Traditional Chinese Medicine, Beijing, China, Department of Surgery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
- 2Department of Urology, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China, Department of Surgery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
- 3Department of Surgery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Human papillomavirus type 16 (HPV-16)-associated penile squamous cell carcinoma (PSCC) poses considerable therapeutic challenges, especially in its advanced stages.Although surgery continues to be the cornerstone of treatment, immunotherapeutic approaches hold a promising alternative for patients unable to endure conventional chemotherapy.A 69-year-old male presented with progressive ulceration of the foreskin over the course of one year, which ultimately extended to the glans, accompanied by inguinal lymph node metastasis. The patient underwent surgical resection, including bilateral inguinal lymph node dissection. Histopathological examination confirmed a diagnosis of HPV-16-related PSCC with concomitant PD-L1 expression. Given the patient's poor tolerance to chemotherapy, he was treated with four cycles of the PD-1 inhibitor tislelizumab, resulting in a partial response.This case underscores the promising potential of immunotherapy as a viable alternative treatment for advanced PSCC in patients who are unable to tolerate chemotherapy. The synergistic integration of surgical intervention, immunotherapy, and psychological support is essential to achieving the best possible outcomes for patients.
Keywords: penile squamous cell carcinoma, Human papillomavirus type 16, Immunotherapy, Lymph node dissection, Checkpoint inhibitors, Advanced cancer
Received: 31 Jan 2025; Accepted: 18 Jun 2025.
Copyright: © 2025 pan, wu, shi and 叶. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: 晋升 叶, Department of Surgery, Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.